316 related articles for article (PubMed ID: 35152908)
1. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.
Tong TML; van der Kooij MK; Speetjens FM; van Erkel AR; van der Meer RW; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Burgmans MC; Kapiteijn E
Trials; 2022 Feb; 23(1):137. PubMed ID: 35152908
[TBL] [Abstract][Full Text] [Related]
2. Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.
Tong TML; Burgmans MC; Speetjens FM; van Erkel AR; van der Meer RW; van Rijswijk CSP; Jonker-Bos MA; Roozen CFM; Sporrel-Blokland M; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Kapiteijn E
Cardiovasc Intervent Radiol; 2023 Mar; 46(3):350-359. PubMed ID: 36624292
[TBL] [Abstract][Full Text] [Related]
3. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.
Tong TML; Samim M; Kapiteijn E; Meijer TS; Speetjens FM; Brüning R; Schroeder TH; El-Sanosy S; Maschke H; Wacker FK; Vogel A; Dewald CLA; Goeman JJ; Burgmans MC
Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1304-1313. PubMed ID: 35922562
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
[TBL] [Abstract][Full Text] [Related]
5. A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma.
Minor DR; Kim KB; Tong RT; Wu MC; Kashani-Sabet M; Orloff M; Eschelman DJ; Gonsalves CF; Adamo RD; Anne PR; Luke JJ; Char D; Sato T
Cancer Biother Radiopharm; 2022 Feb; 37(1):11-16. PubMed ID: 35021863
[No Abstract] [Full Text] [Related]
6. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.
Heppt MV; Amaral T; Kähler KC; Heinzerling L; Hassel JC; Meissner M; Kreuzberg N; Loquai C; Reinhardt L; Utikal J; Dabrowski E; Gesierich A; Pföhler C; Terheyden P; Thoms KM; Zimmer L; Eigentler TK; Kirchberger MC; Stege HM; Meier F; Schlaak M; Berking C
J Immunother Cancer; 2019 Nov; 7(1):299. PubMed ID: 31722735
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanoma.
Estler A; Artzner C; Bitzer M; Nikolaou K; Hoffmann R; Hepp T; Hagen F; Eigentler T; Forschner A; Grözinger G
Acta Radiol; 2022 May; 63(5):577-585. PubMed ID: 34034537
[TBL] [Abstract][Full Text] [Related]
9. Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM).
Rozeman EA; Prevoo W; Meier MAJ; Sikorska K; Van TM; van de Wiel BA; van der Wal JE; Mallo HA; Grijpink-Ongering LG; Broeks A; Lalezari F; Reeves J; Warren S; van Thienen JV; van Tinteren H; Haanen JBAG; Kapiteijn E; Blank CU
Melanoma Res; 2020 Jun; 30(3):252-260. PubMed ID: 31895753
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.
Karydis I; Gangi A; Wheater MJ; Choi J; Wilson I; Thomas K; Pearce N; Takhar A; Gupta S; Hardman D; Sileno S; Stedman B; Zager JS; Ottensmeier C
J Surg Oncol; 2018 May; 117(6):1170-1178. PubMed ID: 29284076
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review.
Heppt MV; Steeb T; Schlager JG; Rosumeck S; Dressler C; Ruzicka T; Nast A; Berking C
Cancer Treat Rev; 2017 Nov; 60():44-52. PubMed ID: 28881222
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A
J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511
[TBL] [Abstract][Full Text] [Related]
13. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
14. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery.
Dewald CLA; Becker LS; Maschke SK; Meine TC; Alten TA; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
Clin Exp Metastasis; 2020 Dec; 37(6):683-692. PubMed ID: 33034815
[TBL] [Abstract][Full Text] [Related]
15. Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal Melanoma.
Dewald CLA; Hinrichs JB; Becker LS; Maschke S; Meine TC; Saborowski A; Schönfeld LJ; Vogel A; Kirstein MM; Wacker FK
Rofo; 2021 Aug; 193(8):928-936. PubMed ID: 33535258
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
17. Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial.
Olofsson R; Ny L; Eilard MS; Rizell M; Cahlin C; Stierner U; Lönn U; Hansson J; Ljuslinder I; Lundgren L; Ullenhag G; Kiilgaard JF; Nilsson J; Lindnér P
Trials; 2014 Aug; 15():317. PubMed ID: 25106493
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
20. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.
Artzner C; Mossakowski O; Hefferman G; Grosse U; Hoffmann R; Forschner A; Eigentler T; Syha R; Grözinger G
Cancer Imaging; 2019 May; 19(1):31. PubMed ID: 31146793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
